Bononi DMPharmacotherapyOlderAdultFinal...2/24/20 2 Establish Goals of Therapy Case • 74 year old...
Transcript of Bononi DMPharmacotherapyOlderAdultFinal...2/24/20 2 Establish Goals of Therapy Case • 74 year old...
![Page 1: Bononi DMPharmacotherapyOlderAdultFinal...2/24/20 2 Establish Goals of Therapy Case • 74 year old male, T2D x 20 years • A1c had been 7.2%, recently 9.0% • Glyburide, metformin](https://reader034.fdocuments.net/reader034/viewer/2022042419/5f360f52ba50774f6f6fc1ef/html5/thumbnails/1.jpg)
!"!#"!$
%
!"#$"%&'(&)$*+","-&./*01*2',/"0*34&$5&,/"&678"0&98:7,.*,0$2$*&;<&='5'5$>&?)?*02/&@>ABAB
Page 2
Page 3
!""#$%&'()$(*+%,-)-.(/%0%1-2-0)(+0(345-#(!564).
! "#$%&'(#)*+,%'#*,-*$)./%01! "2%'3%$.*45$./2.5$(,5#
6 7(-.#$1'.6 8)%/9%:,',+(:
! ;(5(9(<.*/(#=#6 >10,+'1:.9(%6 ?86 7(0(@#
![Page 2: Bononi DMPharmacotherapyOlderAdultFinal...2/24/20 2 Establish Goals of Therapy Case • 74 year old male, T2D x 20 years • A1c had been 7.2%, recently 9.0% • Glyburide, metformin](https://reader034.fdocuments.net/reader034/viewer/2022042419/5f360f52ba50774f6f6fc1ef/html5/thumbnails/2.jpg)
2/24/20
2
Establish Goals of Therapy
Case• 74 year old male, T2D x 20 years• A1c had been 7.2%, recently 9.0%• Glyburide, metformin- doses recently increased to 20 mg glyburide
and 1000 mg bid• More forgetful and disoriented recently• Blurry vision, nocturia• PMH HTN, HLD• No SMBG• PE remarkable for older than stated age, oriented to person and
place only, BMI 27.4, BP 165/95, absent pedal pulses and monofilament sensation
• eGFR 36 ml/min/1.73m2, urine alb/Cr 279 mg/g
What would be your target HbA1c for this patient ?
• A. Less than 9% and ≥8.5%• B. Less than 8.5%• C. Less than 8.0% and ≥7.5%• D. Less than 7.5%
Page 8
Which Target??
![Page 3: Bononi DMPharmacotherapyOlderAdultFinal...2/24/20 2 Establish Goals of Therapy Case • 74 year old male, T2D x 20 years • A1c had been 7.2%, recently 9.0% • Glyburide, metformin](https://reader034.fdocuments.net/reader034/viewer/2022042419/5f360f52ba50774f6f6fc1ef/html5/thumbnails/3.jpg)
!"!#"!$
%
!"!#$%&'((%)*%*+,-.&'/%+,'0-/+
!"#"$%&%# '#%"&$%(&)*+",)-+#).+(/#%0("(& 123,&4!"#$%&'$ ()*+,+*-./+01
! 2345&$678$97:;$)7)<81=).);$.*-/;:! 2>4?$+6$+;$@.)$A1$.@B+1,1*$C+;B7-;$:+=)+6+@.);$
BD<7=/D@19+.$78$7;B18$.*,18:1$1661@;:$76$;81.;91);E
! 2F&$678$;B7:1$.;$8+:GH
I81<8.)*+./$=/-@7:1$%9=J*K' F5L"M5I1.G$<7:;<8.)*+./$=/-@7:1$%9=J*K'$ 2"F5
9"#"$%!"#$%&%'()#*%$%&'()*+(,-../-0+$
E!<<87<8+.;1$<.;+1);:! NB78;$*-8.;+7)$76$*+.A1;1:! OPQ$;81.;1*$7)/D$C+;B$/+61:;D/1$78$
91;6789+)! K7)=$/+61$1R<1@;.)@D! S7$:+=)+6+@.);[email protected]*+7,.:@-/.8$*+:1.:1
H!;$8+:G$<.;+1);:! T+:;78D$76$:1,181$BD<7=/D@19+.! K+9+;1*$/+61$1R<1@;.)@D! !*,.)@1*$9+@87L 78$9.@87,.:@-/.8$@79</+@.;+7):! UR;1):+,1$@7978A+*$@7)*+;+7):! K7)=L:;.)*+)=$OPQ$+)$CB+@B$!"#$=7./$B.:$A11)$
*+66+@-/;$;7$.;;.+)$*1:<+;1$+);1):+,1$16678;:
Algorithm for Individualizing Glycemic Targets
10!"#$%&'()%*%+,-+./*0%""%+1-+)2+$&3+!""#$"%&'"#(&)3+45667689:889'88;3+
<%*0&=+#/2%>$2)?-+$?0)@)A2-+BA/C&)?*)$D&)-+)EF)&&)A2+")&G'F$@)+F$H$F%2%)"-+$A?+F/#H@)0)A"%>)+"IHH/@2+"="2)#"
J)""+#/2%>$2)?-+A/A$?0)@)A2-+&%#%2)?+%A"%*02-+H//@+")&G'F$@)+F$H$F%2%)"-+$A?+C)$B+"IHH/@2+
"="2)#"
J)""+#/2%>$2)?-+A/A$?0)@)A2-+&%#%2)?+%A"%*02-+
!"#$%&"&$'&($&)&*'$+$&)"',(-./'&)"
0#1&23#$(*'.+-'"4J/C ./?)@$2) <%*0
!./'()/+.2(5+#(.-"95 98 85 88 K5 K8 L5 L8
6'"(."(+,7-./'&)5+#(.-"8 65 68 45
8/%(-+$&*&-9',+$&),'/'&)"M/A) ,)C+/@+#%&? .I&2%H&)+/@+")>)@)
!"#$%&"&$'&($&)&*'$+$&)"',(-./'&)"
:"/.93'"%(,+;."$73.-+$&*13'$./'&)"M/A) N$@?%/>$"FI&$@+?%")$")
1$@&=+#%F@/>$"FI&$@ O?>$AF)?+#%F@/>$"FI&$@
<&"/+')/()"';( =(""+')/()"';( =(."/+')/()"';(>?@A B?@A C?@A
!"#$%&'($%()%*'+,-&(./-*()/%%'+*0(1%"2'(%3(4/-&"56
! Few long term studies in older adults demonstrating benefits of intensive glycemic, BP, and lipid control.
! Poor diabetes control is associated with decline in cognitive function.
! Cognitive impairment makes it challenging to help patients reach individualized glycemic, BP, and lipid targets.
! Polypharmacy/pill burden/complexity of regimen! COST!!!
!"#$%&'$()*"+),-&.$/$*+),-
! "#$%& '$()*+$,%-.$#$/'$012$3)42$5&61)*)7.$)3-0)83.1*$*09)16$64%:;8)2.$#<$36$20)4%$012$3.*=&83)1$><<<$36$:)2$?$@>5$A?<B$012$.CDE FG$34H3)1H>?"F$3I$?$J0*).1*$(0K$0K9.2$*&$2&$+&3.$64;5&K.$3&1)*&8)16L$(+)5+$+.$2)2$.880*)5044%?$F$*)3.K$&7.8$*+.$-0K*$M$(..9K$+.$+02$(+0*$0--.08.2$*&$:.$N8012&3O$3)2P20%$64;5&K.K?
! Q.$04K&$5&3-40)1.2$&=$(09)16$;-$K(.0*)16$0*$1)6+*L$:;*$1.7.8$5+.59.2$+)K$64;5&K.$4.7.4K?
![Page 4: Bononi DMPharmacotherapyOlderAdultFinal...2/24/20 2 Establish Goals of Therapy Case • 74 year old male, T2D x 20 years • A1c had been 7.2%, recently 9.0% • Glyburide, metformin](https://reader034.fdocuments.net/reader034/viewer/2022042419/5f360f52ba50774f6f6fc1ef/html5/thumbnails/4.jpg)
!"!#"!$
#
!"#$"%&''()&$"%*)+,-%.)/0%/&12,3%&4-%2112$0#52,3%(2-+$2%"#/%(#/6%)1%"3')7,3$2.#&8
! "#$%&'()&$'*+&$*,$-./0(12'&$3*$45$6-$'72./#! 8#$9:23);$-./0(12'&$3*$-.26&<212'&! =#$9:23);$-./0(12'&$3*$.2>7-.2<32>! ?#$9:23);$6&3,*162>$3*$.2>7-.2<32>! @#$A*>&$*,$3;&$70*B&
!"#$%&"'()*+! "#$%&'()*&+#,-*.)/+0&/.1+%#2&/-,30#14-0513'-,'
Hypoglycemia and Mortality
15
!""#$%&'()*+(, !-./0)1)
!"##$%&!'(&$)&*#+&!"#+&,-.-/01-234111534111+
$1)2&(3&4(5*./1*0&1-&'.*16-*)&71*+&869656&:0;(</0,6=1.
$1)2&(3&:0;(</0,6=1.&71*+&>.,+&?@&"+.-<6&1-&A;B.*6B&!?"
!"#$%#
&'#
!(#
$)*+
$%#
?@&!"#$"%&" ?@&'(#$"%&"
,-./0.102/-3/45632/-3/4563,-./0.102/-3/4563
!"#$%&"'()*+,-.*/0-1+'2$3/
!"#$%&#'()"*"+#%*$,#$+,
! "#$%&'()%! *%+(#%')%,$%&! -.&/0(,'-+%&/0(,'%12,/0/13! 45,)%&'$6&(1/5,'5.'$/(7%1%8
! 9%6&5:(123! ;%,(#'/+:(/&+%,1! <&%=/568'23:5)#30%+/(
-%)".$/*"0'"&1'2*%"#3%&#'4"+#/*,
! >/88%$'+%(#8! ?#%=(1%$'-@A
>/##%&'>?B'%1'(#C'!"#C'DE@E'F(,'GHIJEK7LJJJC'$5/K'@EC@@IMN7+OC7LJJJC @M
![Page 5: Bononi DMPharmacotherapyOlderAdultFinal...2/24/20 2 Establish Goals of Therapy Case • 74 year old male, T2D x 20 years • A1c had been 7.2%, recently 9.0% • Glyburide, metformin](https://reader034.fdocuments.net/reader034/viewer/2022042419/5f360f52ba50774f6f6fc1ef/html5/thumbnails/5.jpg)
!"!#"!$
%
!"#$%&'%#(%$)"*)+,-"./,(%012
! "#$%&'&()*+,-./0#1#$&/21+/02%$)-+3)$*+/#%45-&#%*+&66&'27&1&'.8! 9//&:)%'-! ;211-! <)/566)%'+0.,#$1./)=&2+2%:+0.,#$1./)=&2+5%2>26)%)--! <)462/'#6.+:&27)')-! ?)=)%'&2+! "@+)()%'-
A "26:&2/+25'#%#=&/+%)56#,2'0.A "26:&2/+&-/0)=&2A 9%$&%2A ;2'21+2660.'0=&2
17!"#$%&'("#)*!+)%,)"&-)!"#$%&'(&)%*-)./012.03'455&)067089:-
!"#$%&#'%()*%+,'-
!"#$%&'($)*+&$,-$+&".+%
! "#$%&'()*++(+&*,)-(.#(/001*/2&#-(3$'&(2/,'$*4! 5#-,2#(+#-#4'/16(/2'$7$'6! 8++#++(4,'1$'$*4/)(+'/',+! 87*$-(1#+'1$2'$7#(-$#'+(/4-()$9$'(2*4+,90'$*4(*:(+$90)#(+,%/1+
!"#$%&'()
!"!"#$ %&!'()*+(!,&-./*!01.+0&2).(0+()/3&0+(!4
"+05!0&678&!(&+.4&!"#$%&'(&)%*4&9:;<=9>?9:<@9>A4
#$%&'($)*+,- .*/01-(
2*,'30 4(,'305(&66
7*8-(595:*8,0&/1,8-1$ ;&801-,8<,)-0*<5,=5*:>7 ?@"5+A9+,89BCD@5+!
:-601&,80*60,8-(5-<E*16*5*==*)06 F&<*1-0*
;-1<,-) .*/01-(
G&8* .*/01-(
H*0&-),<&6,6 .*/01-(
>*I5-<E*16*5*E*8065&15%&66,J(*5J*8*=,06 K6*5I,035)-/0,&8 A,L*(,3&&<5&=5-<E*16*5*==*)06 K8)*10-,85*==*)0>*I5-<E*16*5*E*8065&15%&66,J(*5J*8*=,06 K8)*10-,85*==*)0M
!"#$%%"&'"'()$*(+,,(-./0"&/12(3&,"11(4$&/*.0&'0#./"'($*(5$/(6$,"*./"'
![Page 6: Bononi DMPharmacotherapyOlderAdultFinal...2/24/20 2 Establish Goals of Therapy Case • 74 year old male, T2D x 20 years • A1c had been 7.2%, recently 9.0% • Glyburide, metformin](https://reader034.fdocuments.net/reader034/viewer/2022042419/5f360f52ba50774f6f6fc1ef/html5/thumbnails/6.jpg)
!"!#"!$
%
!"#$%&'(')*+&%,-+./0*0
1##2%/.3/4/*+&0
5610
7.089/.%:4,0,9;%4,0,9<)980;%)&'=/>'?@
A89B+.C98&',0
!"#$%&'()
!"##$%&'()*&+",-.$
/(0"%&'()*&+",-.
*)(#(+,-.&"+#'")# /00(#(%)+,-.&"+#'")#
DC)+-9C('=/,%E/0F%G/*3%H.*/3C)'&-9C('=/(%H-'.*0%H??'?%*+%I'*B+&=/.
21!"#$%&&%'()'*+',-.'!"#$%&'(&)%*.'/01231456/78626.
!"#$%&'()%*"+,'-"./01+2"/.,/ 3415$6$."/+'7!(893$+:! "#$#%&'(&)*'$ +,$-).#$#/! 0#1#%&'(&)*'$ +2#34'5#/! 671#%&'(&)*'$ +8#30'#$"6/! 639:%&'(&)*'$ +;96%])/
!"#$%&'()%*"+,'-"./01+2"/.,/'3415$6$."/+'7!(893$+:
!"
!"#$%&'&()*+,-./0+,-)1/&/(,21-3(./40(,&21.+(.+5C&'&/-89+.)13+&*+(,)&:(104,+5&%;!&'&21(<+)1/&=+)-(/12-.1.5&+>7? '&+.)1@()+2&90-@+,40(,&:10),()1-8&,()+5&AB%&'&)CD+&B&21(<+)+.E
>(,<+,&!FG&+)&(0E&!"#$%&'(&)%*E&BHIJ5BKLBHJMBKNE
#$%&'($)*+,- .*/01-(
2*,'30 4&55
6*7-(898:*7,0&/1,7-1$.&08,7;,)-0*;8<&18*:=6 >?@8+49+,79ABC"8+!
:*7,0-(8+$)&0,)8,7<*)0,&75
D&55,E(*8E*7*<,08&<8*+%-'(,<(&F,7
:-501&,70*50,7-(8-;G*15*8*<<*)05 .*/01-(
H-1;,-)IH#= D&55,E(*8E*7*<,08&<8*+%-'(,<(&F,7
H-1;,-)JJKLHMN D&55,E(*8)-1;,&G-5)/(-18E*7*<,0
O&7* H-7-'(,<(&F,78P-17,7'
Q*0&-),;&5,5 NQK8&))/11,7'8,78R!N8,78G-1,&/58501*5585*00,7'5
=*P8-;G*15*8*G*7058&18%&55,E(*8E*7*<,05 S5*8P,038)-/0,&7 4,T*(,3&&;8&<8-;G*15*8*<<*)05 S7)*10-,78*<<*)0=*P8-;G*15*8*G*7058&18%&55,E(*8E*7*<,05 S7)*10-,78*<<*)0U
!!"#$!"#%&'()*)'+%,*-*./.+*%'+%!(('0)-*)'+%'1%,2345%6+7)8)*'9(%:)*7%;<!
! "#$%&''()*%+,-)./(.,012! 3+*456.,.-+0%)70+&%-78&)*%'&,0+,(.9%(*.%&-%:;<=>%+,?+6+0&)*%@+0?%,&%'?7,A.*%+,%'()).,0%).'&BB.,970+&,*
! "#$%9+7A,&*+*%B72%6.%B+**.9%&)%9.172.9%9(.%0&%702C+'71%C).*.,070+&,%+,8&18+,A%1&@.)50?7,57,0+'+C70.9%A1('&*.%1.8.1*%&)%&0?.)%B+*1.79+,A%176&)70&)2%871(.*D =?+*%702C+'71%C).*.,070+&,%?7*%6..,%*..,%@+0?%&0?.)%7,0+?2C.)A12'.B+'%7A.,0*%1&,A%6.-&).%0?.%+,0)&9('0+&,%&-%:;<=>%+,?+6+0&)*%
!""#$%E%9+76.0+'%4.0&7'+9&*+*F%:;<=>%E%*&9+(B%A1('&*.%'&0)7,*C&)0.)%>G
H7,9.1*B7,%IJ%.0%71G%!"#$%& '&(%)G%>KLMF>>NOPQ5OM>G
![Page 7: Bononi DMPharmacotherapyOlderAdultFinal...2/24/20 2 Establish Goals of Therapy Case • 74 year old male, T2D x 20 years • A1c had been 7.2%, recently 9.0% • Glyburide, metformin](https://reader034.fdocuments.net/reader034/viewer/2022042419/5f360f52ba50774f6f6fc1ef/html5/thumbnails/7.jpg)
!"!#"!$
%
Page 25
!"#$%&'()"*+,-.,/0*1,-2-3,$,/0'4-5&'(*606-7!8.2-3569
! "#"$%&'(" )*+(,-".$/*+"&&%0! (,1%21,&'(" )3-,1'4'&+0! 1'-%21,&'(" )5'4&.6%0! 1'#'7"$%&'(" )8+#,9'%0! 7"9%21,&'(" ):6"9;'4/<=+>"17,7 ).-%100
!"#$%&'()"*+,-.,/0*1,-2-3,$,/0'4-5&'(*606-7!8.2-3569
!"!"#$%&'&()*+,-./0+,-)1/&/(,21-3(./40(,&21.+(.+5C&'&/-89+.)13+&*+(,)&:(104,+5&#,#0 '&/,+()1818+&/0+(,(8/+;
<(,=+,&!>?&+)&(0;&!"#$%&'(&)%*;&@ABC5@DE@ACF@DG;
#$%&'($)*+,- .*/01-(
2*,'30 4&55
6*7-(898:*7,0&/1,7-1$;<*7-0,=*87&08,7=,)-0*=8,>8?1?( @AB8+49+,7
C&55,D(*8D*7*>,08&>8(,1-'(/0,=*
:-501&,70*50,7-(8-=E*15*8*>>*)05 F&=*1-0*
?-1=,-)G?#H C&55,D(*8D*7*>,08&>8(,1-'(/0,=*
?-1=,-)IIJK?LM C&55,D(*8)-1=,&E-5)/(-18D*7*>,0
N&7* .*/01-(
O*0&-),=&5,5 .*/01-(
H*P8-=E*15*8*E*7058&18%&55,D(*8D*7*>,05 Q5*8P,038)-/0,&7 4,R*(,3&&=8&>8-=E*15*8*>>*)05 Q7)*10-,78*>>*)0H*P8-=E*15*8*E*7058&18%&55,D(*8D*7*>,05 Q7)*10-,78*>>*)0S
!"#$#%"&'( )$#%"&*+$,-,./0"1"%23+,4!))-"+5
! "#$%&"#'(#$ )*+%,-.$(%/! 0%1%&"#'(#$ )2$&"34%/! 0#(%&"#'(#$ )5%$67#%/
!"#$#%"&'()*$#%"&+,$)-)./0"1"%23,)4!**-",5
!"!"#$%&'&()*+,-./0+,-)1/&/(,21-3(./40(,&21.+(.+5C&'&/-89+.)13+&*+(,)&:(104,+;
<(,=+,&!>?&+)&(0;&!"#$%&'(&)%*;&@ABC5@DE@ACF@DG;
#$%&'($)*+,- .*/01-(
2*,'30 .*/01-(
4*5-(6768*5,0&/1,5-1$9&:*6-;</:0+*5065*)*::-1$6=*>)*%06(,5-'(,%0,5?@AA*)0,B*6,561*;/),5'6-(C/+,5/1,-
8-:01&,50*:0,5-(6-;B*1:*6*AA*)0: .*/01-(
D-1;,-)ED#F G&::,C(*61,:H6A&16:->-'(,%0,56-5;6-(&'(,%0,5
D-1;,-)IIJKDL9 .*/01-(
M&5* .*/01-(
N*0&-),;&:,: .*/01-(
F*O6-;B*1:*6*B*50:6&16%&::,C(*6C*5*A,0: P:*6O,036)-/0,&5 Q,H*(,3&&;6&A6-;B*1:*6*AA*)0: P5)*10-,56*AA*)0F*O6-;B*1:*6*B*50:6&16%&::,C(*6C*5*A,0: P5)*10-,56*AA*)0R
![Page 8: Bononi DMPharmacotherapyOlderAdultFinal...2/24/20 2 Establish Goals of Therapy Case • 74 year old male, T2D x 20 years • A1c had been 7.2%, recently 9.0% • Glyburide, metformin](https://reader034.fdocuments.net/reader034/viewer/2022042419/5f360f52ba50774f6f6fc1ef/html5/thumbnails/8.jpg)
!"!#"!$
%
!"#$"%&'(')"* +',-."/-$-0"12',-/-3-0"12',45)$-0"122222222222222222222222222222222222222222222$"/&',-6-0"126&%"',-6-0"7
!"!"#$%&'&()*+,-./0+,-)1/&/(,21-3(./40(,&21.+(.+5C&'&/-89+.)13+&*+(,)&:(104,+5&;<=&'&901812+5&">&'&.40:-8?04,+(@
;(,A+,&!BC&+)&(0@&!"#$%&'(&)%*@&DEFG5DHIDEGJDHK@
!" #$%
#$%&'($)*+,- .&/*0-1*2324*5*0* .,(/
6*,'71 8-,9
:*9-(2328*9,1&;0,9-0$ .&0*27$%&'($)*+,-20,4<
8-410&,91*41,9-(2-/5*04*2*==*)14 >*;10-(
?-0/,-)@?#A .&0*2?#A20,4<
?-0/,-)BBCD?EF G
H&9* >*;10-(
I*1&-),/&4,4 >*;10-(
A*J2-/5*04*2*5*9142&02%&44,K(*2K*9*=,14 L4*2J,172)-;1,&9 M,<*(,7&&/2&=2-/5*04*2*==*)14 L9)*01-,92*==*)1A*J2-/5*04*2*5*9142&02%&44,K(*2K*9*=,14 L9)*01-,92*==*)1G
!"#$%&'"()*+,-%+.&/0$,1,2*3+&4!',+5&4%)%31*+.5
!"!"#$%&'&()*+,-./0+,-)1/&/(,21-3(./40(,&21.+(.+5C&'&/-89+.)13+&*+(,)&:(104,+;
<(,=+,&!>?&+)&(0;&!"#$%&'(&)%*;&@ABC5@DE@ACF@DG;
#$%&'($)*+,- .*/01-(
2*,'30 .*/01-(
4*5-(6768*5,0&/1,5-1$ .*/01-(
8-901&,50*90,5-(6-:;*19*6*<<*)09 =&:*1-0*
>-1:,-) .*/01-(
?&5* .*/01-(
@*0&-),:&9,9 .*/01-(
A*B6-:;*19*6*;*5096&16%&99,C(*6C*5*<,09 D9*6B,036)-/0,&5 E,F*(,3&&:6&<6-:;*19*6*<<*)09 D5)*10-,56*<<*)0A*B6-:;*19*6*;*5096&16%&99,C(*6C*5*<,09 D5)*10-,56*<<*)0G
!"#$%&'#(#)*(#&)*+,-!./+01,-2#&3'#4$%&)*0
!"
!"#$%&'(%)$#*%)+,-#./-('0#1%)23)4.56
789:;)<)'(=%&#*>/%&#(->)>'&$-#?'*>@/'&)$-*%'*%A)9BC)<)>#1.%*(-?%)=%'&()D'-/@&%6
E'&F%&)7GH)%()'/6)!"#$%&'(&)%*6)I3JKAI2LI3KMI2N6
#$%&'($)*+,- .*/01-(
2*,'30 4-,5
6*5-(7874*5,0&/1,5-1$ .*/01-(
4-901&,50*90,5-(7-:;*19*7*<<*)09 .*/01-(
=-1:,-)>=#? @&:*1-0*
=-1:,-)AABC=DE @-$71*:/)*7901&F*71,9F
G&5* @&:*1-0*7<1-)0/1*71,9F
H*0&-),:&9,9 .*/01-(
?*I7-:;*19*7*;*5097&17%&99,J(*7J*5*<,09 K9*7I,037)-/0,&5 L,F*(,3&&:7&<7-:;*19*7*<<*)09 K5)*10-,57*<<*)0?*I7-:;*19*7*;*5097&17%&99,J(*7J*5*<,09 K5)*10-,57*<<*)0M
!"#$%$&$#'( ')*+,"("-,./0.)$ 1$%2#'0$
!"!"#$%&'&()*+,-./0+,-)1/&/(,21-3(./40(,&21.+(.+5&6#7897&'&:,-;-/,1<)1=+&;+.>0()+ ?41/@&,+0+(.+5&#AB&'&/-=C+.)13+&*+(,)&D(104,+E
F(,:+,&!GH&+)&(0E&!"#$%&'(&)%*E&IJKL5IMNIJL8IMOE
#$%&'&(&%)* +#,-.,
/01$2%03&*4) 5&678)% 5&678)%
9&42:7 5&678)% 5&678)%
,&;)%<=<>&;47$684;)80 5&678)% 5&678)%
>)'78$4;7&'74;)%<)?(&8'&<&@@&37' A4%? A$?&8)7&
#)8?4)3B#/C 5&678)% 5&678)%
#)8?4)3--DE#FG +&;&@47 E)@&
+$;& 5&678)% 5&678)%
H&7$)34?$'4' 5&678)% 5&678)%
C&I<)?(&8'&<&(&;7'<$8<1$''4J%&<J&;&@47' K'&<I47:<3)674$; L4M&%4:$$?<$@<)?(&8'&<&@@&37' K;3&87)4;<&@@&37C&I<)?(&8'&<&(&;7'<$8<1$''4J%&<J&;&@47' K;3&87)4;<&@@&37N
![Page 9: Bononi DMPharmacotherapyOlderAdultFinal...2/24/20 2 Establish Goals of Therapy Case • 74 year old male, T2D x 20 years • A1c had been 7.2%, recently 9.0% • Glyburide, metformin](https://reader034.fdocuments.net/reader034/viewer/2022042419/5f360f52ba50774f6f6fc1ef/html5/thumbnails/9.jpg)
!"!#"!$
%
!"#$%&"
!!!"#$%&'&()*+,-./0+,-)1/&/(,21-3(./40(,&21.+(.+5C&'&/-89+.)13+&*+(,)&:(104,+;
<(,=+,&!>?&+)&(0;&!"#$%&'(&)%*;&@ABC5@DE@ACF@DG;
"#$%&'#()*+, -%.)/,0)10%12)3)/)
4)+&50 6,+7
8)7,'1916)7+0%:/+7,/# -%/)15#$%&'#()*+,1/+2;
6,20/%+70)20+7,'1,.3)/2)1)<<)(02 =):0/,'
>,/.+,(?>"@ -%/)1>"@1/+2;
>,/.+,(?AB>CD =):0/,'
E%7) =):0/,'
F)0%,(+.%2+2 =):0/,'
@)G1,.3)/2)1)3)7021%/1$%22+H')1H)7)<+02 I2)1G+051(,:0+%7 J+;)'+5%%.1%<1,.3)/2)1)<<)(02 I7()/0,+71)<<)(0@)G1,.3)/2)1)3)7021%/1$%22+H')1H)7)<+02 I7()/0,+71)<<)(0K
!"#$%#&'()*+,)&-.'/.01#)2#32+.4*-52)*-
34
!"#$% &$'#%()*+ ,#-.()*+ /01-%23$()*+ 43$'25#1-%23$'
6-'-7
6!7 !"# #"$% $%"$&'()*+)(,(-./,01,203+4(2*5,67809573):-*,30:8*();,+0,-2.45-2,*2*509.
82#$9)*+:+,+%)$:+925;+&
<$"#=0,
8(020423);,8)*/>
?8,+0,!#@ A)..,203+4(2*5,67809573):-*,30:8*();,+0,=BC
6-'-78
,1-$
52-7 <+952#$.=>
?@@ D%EF <!"G $!"!#
• H2I)3+,G%,:-2,J)10(),*,:)*5• H2;-3*+);,10(,6-9657,-2.45-2 ().-.+*2+,-2;-K-;4*5.• ?.),3*4+-02,L6)2,:)*.4(-29 ;0.*9),+0,*K0-;,
-2*;K)(+)2+,0K)(;0.)
,1-$
52-7
<+952#$ <%EF"$ <!"G ?8,+0,M• N4.+,J),-2I)3+);,G%"#F,:-2,J)10(),*,:)*5• H2I)3+-02,L-+6,0(,*1+)(,*,:)*5,3045;,-23()*.),(-./,10(,
67809573):-*
0-A#$,BC)#-A8252)-)*+D)-A$'4*"#2+;.)*-52)*
O%EF <%EF"!EF <G"F• P*2,J),*;:-2-.+)();,%"$F,:-2,J)10(),*,:)*5• A)..,(-./,01,80.+8(*2;-*5,67809573):-*,30:8*();,+0,
()945*(,-2.45-2
!"#$%&'&()"*"+,*-"*("%&.%,/"01)*.,)2
3"41),50,+,60,6(2
789:"7,;(/*<"8/1(*=&6,"9*.,01/62
>1.%&))&"#",("*<2"!"#$%&'(&)%*2"?@ABCADEF?G5FBF2"9;=;<&6"H"I5F@@"JK16K,6(/*(,0L"&6);<&6"+/,)K/&'&6."&6M1/=*(&162"N60&*6*+1<&)E"O&<<P"IQR:"OOS2
!"#$%&"'()"*+",-.,&)"#'
Drugs@FDA. http://www.accessdata.fda.gov/Scripts/cder/DrugsatFDA. Newton C, et al. AACE Annual Meeting. 2013 [abstract 271]. Segal AR, et al. Am J Health Syst Pharm. 2010;67:1526-1535.
! "#$%&'#()*#$($'+#','-.#/&0(1*2%-*(/3*(1'$4(5,(25$'#+(*1151$(.#2(30)5+&0-*6'-(*7*#/$
! 8*#$(-56)&*/*&0(*&'6'#./*(/3*(#**2(,51(-5#7*1/'#+(25$*$(9.$*2(5#(/3*(75&%6*(5,('#$%&'#('#:*-/*2
! ;5$'#+(*1151$(<'/3(=>?@@('#$%&'#(7'.&$(.1*(-5665#(.#2(2.#+*15%$(9%/(-.#(9*(.75'2*2(<'/3(#*<&0(.7.'&.9&*()*#$
A ?>,5&2(3'+3*1('#$%&'#(25$*(1*&./'7*(/5(/3*($.6*(75&%6*(5,(.(=>B@@('#$%&'#
!"#$%#&'(&)"# *#)&+,-. *#)&+,/)(0 *#)&+,1%#
=>B@@ B@@ B@@@CB@(%#'/$()*1(7'.&D
E@@CE(6FG)*#D
=>H@@ H@@ I5/ .7.'&.9&*('#(7'.&$ J@@CE(6FG)*#D
=>E@@ E@@ I5/ .7.'&.9&*('#(7'.&$ K?@CBL?(6FG)*#D
=>?@@ ?@@ B@M@@@CH@(%#'/$G7'.&D
B?@@CBL?(6FG)*#D
35
!"#$%$&'(#$)*!+("#,*&"%*-($+.#
! "#$%&'(&)**#+#',)-&./#01+&0)#,&23$+&4/&4)-),5/*&)0)#,$+&+1/&4/,/(#+$&'(&+1/&)0/,+6 73-(',8-39/)$&2)8&,/0)+/&./#01+&-'$$&4/,/(#+$&'(&:;<=&9/5/>+'9&)0',#$+$&'9&2/+('92#,6 ?,$3-#,&$1'3-*&,'+&4/&.#+11/-*&4/5)3$/&'(&+1/&9#$%&'(&./#01+&0)#,
:)94/9&@AB&/+&)-C&!"#$%& '&(%)C&DE=FGDHIDEFJDHKC@L@C&*+(,-)-./0(&-C&DE=FGMEI7NMJ7FMC!"#$%&'("#)*!+)%,)"&-)!"#$%&'(&)%*-)./012.03'455&)067089:-
!"#$$ %&'()*$+ ,'-&.)/011'2);(<&=#)"#"&>? @A"(&=#,=$% BC=?4"#=$% D%,E>A(=# BFG@0)A%H%5,>A)"?>#=',' $4&"?&4,=$%+)%I%#",=$%+)%I%#",=$%)JK+ &=A"?&4,=$% BLFGM8.)=#N=O=,>A' H"#"?&=E&>P=#+)$"5"?&=E&>P=#+)%(5"?&=E&>P=# B!8F&4H>'=$"'%)=#N=O=,>A' ;H"AO>'%+)(=?&=,>& QC=&%)"H=$)'%R4%',A"#, S>&%'%T%&"( QU@@V)=#N=O=,>A' &=#"?&=5,=#+)'"I"?&=5,=#+)'=,"?&=5,=# QU>5"(=#%8.)"?>#=', CA>(>HA=5,=#% QF&=#=$%' W",%?&=#=$%+ A%5"?&=#=$% XL4&E>#<&4A%"' F&=(%5=A=$%+ ?&=5=P=$%+)?&<O4A=$% X
Y#'4&=# ;'5"A,+ $%,%(=A+)?&"A?=#%+)?&4&='=#%+)&='5A>+)W@!+)A%?4&"A+)=#N"&%$ XX
MN="P>&=$=#%$=>#%' @=>?&=,"P>#% XX
36
![Page 10: Bononi DMPharmacotherapyOlderAdultFinal...2/24/20 2 Establish Goals of Therapy Case • 74 year old male, T2D x 20 years • A1c had been 7.2%, recently 9.0% • Glyburide, metformin](https://reader034.fdocuments.net/reader034/viewer/2022042419/5f360f52ba50774f6f6fc1ef/html5/thumbnails/10.jpg)
!"!#"!$
%$
TECHNOLOGY FOR TYPE 2 DIABETES MANAGEMENT
Glycemic Management of Type 2 Diabetes
37
!"#$%&'%()*+%,%-&./+0+12%33456345%7+89::+';.0&9'1
38
!"#$%&'()*#%$%+",-(.//"0$#(',-0"1%.(%&(!23(45"&($5"(6"#7,$#(.6"(7#"8 $*9: ;*8%/-(<"5.+%*6: ;*8%/-()5.61.0*,*'%0($6".$1"&$
=>?@(/.#$%&'(),.#1.(',70*#"A(>>?@()*#$)6.&8%.,(',70*#"A(B;C?@(#",/D1*&%$*6%&'(*/(<,**8(',70*#"A(!23@($-)"(2(8%.<"$"#E
F.&8",#1.&(GF@("$(.,E(!"#$%&'(&)%*E(2HIJA2IK#7)),(IL9IDMNE
!"#$#%&'$#()%*+%: O&$6*870"(.$(8%.'&*#%#: >"6#*&.,%P"(/6"Q7"&0-(*/(
$"#$%&': R#"(B;C?(6"#7,$#($*(%&/*61(
8"0%#%*&#(.<*7$(45"$5"6($*($.6'"$(=>?(*6(>>?(/*6(.&-(%&8%+%87.,().$%"&$
,#%&'$#()%*+%: S,,().$%"&$#(7#%&'(%,%&(
#5*7,8($"#$(',70*#"T U2($%1"#(8.%,-T C"/*6"(.&-(%&V"0$%*&(*/(%,%&
: ;*6"(/6"Q7"&$(B;C?(K./$"6(1".,#(*6(%&($5"(1%88,"(*/($5"(&%'5$L(1.-(<"(6"Q7%6"8T =6"Q7"&$(5-)*',-0"1%.T W*$(.$(SIX($.6'"$
!"#$%&'"()#*(+',*(-.'/)011234#*-"#-*&5'#&6#$),',*(-.'/)01783
291Baseline
29:
298
29;
;9<
;91
;9:
;98
;9;
=9<
>? >@ >8 >= >?1
A<9@B/!0<9<:3
!"#$%&'"
()'*
+(!,
-(./
0
!"#$%&'%()*&+'*,%-&*.%/0123*%4,&'5%6',78&'
!"#$%&'()*+%',-(.,/%0.,123%456#$%7+/89:,-)(,.)-0%,8%;/,,<%0/1',7+3%4=#$%7(.1'(1.+<%(+7()-0%0.,123%=>?$%(@2+%>%<)&;+(+7A
B,/,-7C@%DE$%+(%&/A%!"#$%&%'()#*%A%>FGG3HIJ>K>9>KLA
!"# MANOPFAFMQ
MALOPFAGQ
MA>OPFAGQ
LANOPFAGQ
MAFOPFAGQ
MAFOPFAGQ
4=# MANOPFAFLQ
MAROPFAFNQ
LANOPFAFNQ
LANOPFAFNQ
LAKOPFAFNQ
LALOPFAFNQ
39
!"#$%&'&(#$)*$+#(#,$-#./'#$01&2/*#$3/4)'/()45
%(##*'61#$7)8(#9#:2/. 0;
![Page 11: Bononi DMPharmacotherapyOlderAdultFinal...2/24/20 2 Establish Goals of Therapy Case • 74 year old male, T2D x 20 years • A1c had been 7.2%, recently 9.0% • Glyburide, metformin](https://reader034.fdocuments.net/reader034/viewer/2022042419/5f360f52ba50774f6f6fc1ef/html5/thumbnails/11.jpg)
!"!#"!$
%%
Page 41
Older Adult with Diabetes
Medical Complications
Cognitive Function
Geriatric Syndromes
PhysicalFunction
Pharmacologic Considerations
Individualize Targets and Strategies
Standard InterventionsHypoglycemia Prevention Telemedicine
MonitorSupport Educate
Functional Medicine
Engage Family & Social Resources